Why current evidence does not support routine C5 inhibition in STEC-HUS
- 7 July 2026
- journal article
- Published by Elsevier in Kidney International
- Vol. 110 (4) , 804-806
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Deleterious consequences of Shiga toxin in the CNSMicrobiology and Molecular Biology Reviews, 2026
- Volume expansion mitigates Shiga toxin-producing E. coli-hemolytic uremic syndrome in childrenPediatric Nephrology, 2024
- Shiga toxin targets the podocyte causing hemolytic uremic syndrome through endothelial complement activationMed, 2023
- Shiga Toxin–Producing Escherichia coli and the Hemolytic–Uremic SyndromeNew England Journal of Medicine, 2023
- Optimizing therapeutic decision‐making for off‐label medicines use: A scoping review and consensus recommendations for improving practice and research+Pharmacoepidemiology and Drug Safety, 2023
- Efficacy and Safety of Eculizumab in Pediatric Patients Affected by Shiga Toxin–Related Hemolytic and Uremic Syndrome: A Randomized, Placebo-Controlled TrialJournal of the American Society of Nephrology, 2023
- Hyperhydration to Improve Kidney Outcomes in Children with Shiga Toxin-Producing E. coli Infection: a multinational embedded cluster crossover randomized trial (the HIKO STEC trial)Trials, 2023
- Fluid restriction versus volume expansion in children with diarrhea-associated HUS: a retrospective observational studyPediatric Nephrology, 2020
- Eculizumab in the treatment of Shiga toxin haemolytic uraemic syndromePediatric Nephrology, 2018
- Early Volume Expansion and Outcomes of Hemolytic Uremic SyndromePediatrics, 2016